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ABSTRACT
Background: Coffee consumption has been associated with numerous cancers, 
but evidence on ovarian cancer risk is controversial. Therefore, we performed a meta-
analysis on prospective cohort studies in order to review the evidence on coffee 
consumption and risk of ovarian cancer. 
Methods: Studies were identified through searching the PubMed and MEDLINE 
databases up to March 2017. Risk estimates were retrieved from the studies, and 
dose-response analysis was modelled by using restricted cubic splines. Additionally, 
a stratified analysis by menopausal status was performed. 
Results: A total of 8 studies were eligible for the dose-response meta-analysis. 
Studies included in the analysis comprised 787,076 participants and 3,541 ovarian 
cancer cases. The results showed that coffee intake was not associated with ovarian 
cancer risk (RR = 1.06, 95% CI: 0.89, 1.26). Stratified and subgroup analysis showed 
consisted results. 
Conclusions: This comprehensive meta-analysis did not find evidence of an 
association between the consumption of coffee and risk of ovarian cancer.
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INTRODUCTION
Coffee is among the most consumed beverages 
worldwide: in Europe, the geographic area showing the 
highest coffee consumer in the world, people are reported 
to drink 725 million cups of coffee every day [1]. In light 
of its wide consumption, it is an important public health 
goal to assess whether coffee has protective or detrimental 
effects against cancer risk.
Current evidence from epidemiological and 
experimental studies suggests that coffee consumption 
may exert beneficial effects towards non-communicable 
diseases [2]. In particular, coffee consumption has been 
associated with decreased risk of cardio-metabolic 
conditions, including metabolic syndrome [3], diabetes 
[4] and cardiovascular disease [5]. Research on cancer risk 
showed more controversial findings: a summary of evidence 
reported that coffee could have a protective role against the 
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development of various cancers, including liver, colorectal, 
endometrial, oral, melanoma, and prostate cancer among 
others [6–12]. However, other revision of existing literature 
reported contrasting results [13, 14]: this conclusion was 
based on a dose-response meta-analysis of 10 cohort 
studies, and the relative risk (RR) for an increment of 1 
cup/day appeared to be not significantly associated with 
risk of overall cancers [15]. Numerous confounders and 
effect modifiers can have a role in assessing the relationship 
between coffee consumption and health outcomes: for 
instance, recent meta-analyses on coffee consumption and 
various health outcomes pointed out that the ambiguous 
results on cancer mortality and hypertension were due to 
the modifying effect of smoking [16, 17].
Ovarian cancer has a major epidemiological and 
social burden for women worldwide: in 2012, women with 
a diagnosis of ovarian cancer occurred in the last 5 years 
were over 587,000 and 157,000 worldwide and in Europe, 
respectively [18, 19]. In 2013, deaths accounted for 
ovarian cancer were about 158,000 worldwide, together 
with over 4 million disability adjusted life years (DALYs); 
such figure significantly increased from 1990 (2.7 million 
DALYs) and poses ovarian cancer as the worldwide 12th 
contributor of death and disability among cancers [20].
The evidence on the association between coffee 
drinking and the risk of ovarian cancer is quite limited 
and inconsistent. Results of a meta-analysis of prospective 
cohort studies revealed a non-significant positive 
association between coffee drinking and risk of ovarian 
cancer [21]. However, more recent data has been published 
and comprehensive summary of evidence is lacking. Thus, 
the aim of this study is to update current evidence on the 
association between dietary coffee consumption and risk 
of ovarian cancer testing also the dose-response relation.
METHODS
We performed a meta-analysis of prospective cohort 
studies following Meta-Analysis of Observational Studies 
in Epidemiology (MOOSE) protocols throughout design, 
execution, analysis and reporting stages (Supplementary 
Table 1).
Search strategy
To collect and critically review the evidence, we 
performed a comprehensive literature search in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/) and EMBASE 
(http://www.embase.com/) databases, from the earliest 
available online indexing year to March 2017. The search 
was limited to studies published in English. Search 
terms included the following: (coffee OR caffeine OR 
beverages) AND (ovarian) AND (cancer OR carcinoma 
OR neoplasm) (Supplementary Table 2). Titles and abstracts 
of all identified studies were screened by two members of 
the team. Studies were eligible for inclusion in the meta-
analysis if they met the following inclusion criteria: 1) the 
study had a prospective design; 2) the exposure of interest 
was coffee consumption; 3) the outcome was ovarian 
cancer incidence; 4) the investigators reported relative risks 
with 95% confidence intervals for 3 or more quantitative 
categories of coffee consumption. When discrepancies 
over inclusion arose, inclusion criteria were assessed to 
reach a consensus. Reference lists of included manuscripts 
were also screened for any additional study not previously 
identified. When duplicate reports on the same cohort were 
identified, we included the one that provided the largest 
number of cases (or entire cohort) or with the longest 
follow-up for each endpoint of interest.
Data extraction
Data were abstracted from all identified studies using 
a standardized extraction form. Information was extracted 
from each study and consisted of: 1) first author name; 2) 
year of publication; 3) study cohort name; 4) country; 5) 
number of participants; 6) gender of participants; 7) age 
range of the study population at baseline; 8) categories 
of consumption; 9) coffee type; 10) follow-up period; 11) 
endpoints and cases; 12) distributions of cases and person-
years, HRs, and 95% CIs for all categories of exposure; 
13) covariates used in adjustments. Extraction of data was 
performed independently by two authors. Discrepancies 
were discussed and resolved by consensus. The quality of 
included studies was assessed according to the Newcastle-
Ottawa Quality Assessment Scale [22].
Statistical analysis
Highest versus lowest and dose-response meta-
analyses were performed to determine the relationship 
between coffee intake and ovarian cancer risk. The most 
fully adjusted RRs/HRs with 95% CI for all categories of 
exposure were extracted. Random-effects models were used 
to calculate pooled effects, wherein HRs were deemed as 
equivalent to relative risks (RRs) [23]. Heterogeneity was 
assessed through the I2 statistic, which estimates the fraction 
of variance that is due to heterogeneity and by Q test. The 
level of significance for the Q test was defined as P < 0.10. 
The values of I2 statistic ≤25%, 25–50%, 50–75%, and 
>75% indicated no, small, moderate, and significant 
heterogeneity, respectively. The stability of the results 
and potential sources of heterogeneity were examined in 
a sensitivity analysis excluding one study at a time and 
in subgroup analysis according to menopausal status and 
geographical area. Included studies did not provide datasets 
of stratified analysis to test for potential confounders/effect 
modifiers, such as smoking or BMI. Therefore, subgroup 
analyses were only performed according to adjustment 
for smoking status, BMI, education level and alcohol 
consumption. Publication bias was evaluated by a visual 
investigation of funnel plots for potential asymmetry.
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To examine linear and non-linear relationship 
between coffee intake and risk of ovarian cancer, random-
effects dose-response meta-analysis was used. We extracted 
data on the amount of coffee intake, distributions of cases 
and person-years (when available), and RRs/HRs with 
95% CIs for ≥3 exposure categories. In each study across 
categories of consumption, the mean or median intake of 
coffee was assigned to the corresponding RR/HR with 
the 95% CI. When originally in article the range of coffee 
intake was reported , the midpoint of the range was selected 
. When the highest category was open ended, we assumed 
the width of the category to be the same as the adjacent 
category. When the lowest category was open ended, we set 
the lower boundary to zero. Random-effects dose-response 
meta-analysis was performed in two-stages. In the first stage 
the method reported by Greenland and Orsini (that is, GLS) 
was used to calculate study-specific slopes (generalized 
least-squares, GLS) on the basis of results across categories 
of coffee intake taking into account the correlation within 
each set of retrieved HRs [24, 25]. Model of restricted cubic 
splines with 3 knots at fixed percentiles (25%, 50%, and 
75%) of the distribution was applied in non-linear dose-
response. [26]. We combined the coefficients that had been 
calculated within each study by performing random-effects 
meta-analysis with DerSimonian and Laird estimator of 
between study variance (in linear dose-response meta-
analysis) or estimator received by using the method of 
moments (in non-linear dose-response meta-analysis). We 
calculated an overall P-value by testing that the 2 regression 
coefficients were simultaneously equal to zero. We then 
calculated a P-value for non-linearity by testing that the 
coefficient of the second spline was equal to zero. All 
analyses were performed with R software version 3.0.3 and 
we mainly used dosresmeta package (Development Core 
Team, Vienna, Austria).
RESULTS
Study characteristics
We identified a total of 1,340 studies, of which 
1,223 were excluded after review of title, and 104 on 
the basis of abstract (Figure 1). Of the remained thirteen 
publications, four were not included for the following 
Figure 1: Flow chart and process selection of relevant studies exploring the association between coffee consumption 
and ovarian cancer risk.
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reasons: 1) the article did not provide relative risks (or 
similar risk measures) and corresponding confidence 
intervals; 2) the study provided less than three exposures 
of coffee consumption; 3) the article reported on gene 
polymorphism. For the analysis on the association between 
coffee consumption and ovarian cancer risk, nine studies 
were eligible [13, 27–34], of which one was a multi-center 
study [27]. Studies included in the analysis comprised 
787,076 participants and 3,541 ovarian cancer cases. Five 
studies were conducted in Europe [27, 28, 30, 31, 33] and 
four in USA [13, 29, 32, 34]. Three studies provided risk 
estimates for postmenopausal status [13, 29, 33], and three 
for caffeinated and decaffeinated coffee consumption (27, 
29, 34). The follow-up in prospective studies ranged from 
about 11 to 24 years, and the age range at study baseline 
was 25-76 years. Characteristics of the studies included in 
the meta-analysis are provided in Table 1.
Summary relative risk for highest versus lowest 
category of coffee consumption
The summary risk of ovarian cancer for highest 
versus lowest category of coffee consumption was 
RR = 1.06, 95% CI: 0.89, 1.26, with no evidence 
of heterogeneity I2 = 25%, P = 0.24 (Figure 2). No 
publication bias was found after visual inspection of 
Table 1: Characteristics of the cohort studies included in the meta-analysis
Author, year Cohort name, country
Years of study, 
follow-up
Cases; total 
population
Age 
range Adjustments
Larsson 2005 SMC, Sweden 1987–2004, 15.1y (mean) 301; 61,057 40–76y
Age in months, BMI, education, parity, oral contraceptive use, 
and intakes of total energy, fruit, vegetables, milk, and tea.
Silvera 2007 NBSS, Canada 1980–2000, 16.4y (mean) 264; 48,776 40–59y
Age, smoking history, pack-years of smoking, alcohol intake, 
education, BMI, parity, participation in vigorous physical 
activity, menopausal status, oral contraceptive use, energy 
intake, lactose intake, study center, and randomization group.
Steevens 2007 NLCS, Netherlands 1986–1999, 13.3y 280; 62,573 55–69y Age, use of oral contraceptives, parity, cigarette smoking, tea.
Lueth 2008 IWHS, USA 1986–2004, 18y (maximum) 266; 29,060 55–69y
Age, smoking, BMI, age at menopause, parity, oral 
contraceptive use, education level, physical activity, and total 
energy intake.
Tworoger 2008 NHS, USA 1980–2004, 24y (maximum) 507; 80,253 30–55y
Age, parity, oral contraceptive use, postmenopausal hormone 
use, tubal ligation, smoking status, and BMI.
Nilsson 2010 VIP, Sweden 1985–2007, 15y (maximum) 71; 32,178 30–60y
Age, sex, BMI, smoking, education, recreational physical 
activity.
Braem 2012 EPIC, Europe 1992–NA; 11.7y (median) 1,244; 330,849 25–70y
Center, age, parity, oral contraceptive use, BMI, smoking 
status, alcohol consumption, total energy intake, duration of 
breastfeeding, menopausal status, height, educational level.
Hashibe 2015 PLCO, USA 1992–2011; 13y (maximum) 162; 50,563 55–74y
Age, sex, race, education, smoking status, smoking frequency, 
smoking duration, time since stopping smoking for past 
smokers, and drinking frequency.
Lukic 2016 NOWAC, Norway
1991–2013; 13.1y 
(average) 446; 91,767 30–70y
Menopausal status at baseline, smoking status, age at 
smoking initiation, number of pack-years smoked, duration 
of education, BMI, physical activity level, use of oral 
contraceptives, alcohol consumption, number of children, use 
of hormone replacement therapy, and maternal history of breast 
cancer.
Figure 2: Forest plot of summary relative risks (RRs) of ovarian cancer for the highest versus lowest (reference) 
category of coffee consumption.
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funnel plot (Supplementary Figure 1) Two cohorts, 
NOWAC and VIP were excluded from the main analysis, 
as part of their cases are included in the multicentre study 
EPIC. However, an alternative analysis was performed 
by including this cohorts and excluding EPIC study; the 
relative risk was RR = 1.05, 95% CI: 0.88, 1.26; I2 = 20%, 
P = 0.27. Similarly, when taking into account menopausal 
status, no association between coffee consumption and 
ovarian cancer risk was found, and RR = 1.15, 95% 
CI: 0.92, 1.45; I2 = 0%, P = 0.87 (Table 2). Finally, no 
significant differences were found for coffee type or 
adjustment for potential confounders (Table 2).
Dose-response meta-analysis
Eight studies [13, 28–34] were included in dose-
response meta-analysis of prospective studies on coffee 
consumption and ovarian cancer risk, three of which 
provided risk estimates for postmenopausal individuals 
[13, 29, 33]. 
We found no evidence of association between coffee 
consumption and ovarian cancer risk in both analysis 
on total group of women (Figure 3, Table 3) and when 
considering only postmenopausal individuals.
DISCUSSION
In this large meta-analysis of prospective cohort 
studies, we did not find any association of consumption 
of total, caffeinated, and decaffeinated coffee with 
risk of ovarian cancer. Despite a large number of 
studies suggested that an inverse relationship of coffee 
consumption and cancer risks may be mediated by 
various mechanisms, such as reduction of oxidative 
stress and DNA damages, detoxification of carcinogens, 
inhibition of carcinogenesis, and induction of apoptosis 
[35–38], a clear association with ovarian cancer risk could 
not be assessed. Coffee contains thousands of bioactive 
components including polyphenols, caffeine, diterpens and 
melanoidins, which have been shown to reduce oxidative 
stress and exert anti-cancerogenic properties [39, 40]. 
Dietary polyphenol intake has been associated lower 
risk of certain cancers and mortality in meta-analysis on 
prospective cohort studies [41, 42]. A protective effect of 
Table 2: Subgroup analyses of studies reporting risk of ovarian cancer for the highest versus lowest (reference) 
category coffee consumption
Subgroup No. of datasets RR (95% CI) I2 Pheterogeneity
Total 7 1.06 (0.89, 1.26) 25% 0.24
Geographical area
North America 4 1.11 (0.79, 1.56) 62% 0.05
Europe 3 1.05 (0.85, 1.32) 0% 0.98
Menopausal status
Postmenopausal 3 1.15 (0.92, 1.45) 0% 0.87
Premenopausal 0 NA NA NA
Coffee type
Caffeinated 3 1.09 (0.70, 1.68) 78% 0.01
Decaffeinated 3 0.89 (0.66, 1.20) 0% 0.99
Adjusted for smoking
No 1 1.02 (0.62, 1.69) NA NA
Yes 6 1.07 (0.88, 1.31) 37% 0.16
Adjusted for BMI
No 2 1.13 (0.87, 1.45) 0% 0.76
Yes 5 1.05 (0.81, 1.36) 46% 0.12
Adjusted for education
No 2 0.89 (0.62, 1.27) 55% 0.14
Yes 5 1.17 (0.97, 1.41) 0% 0.69
Adjusted for alcohol 
intake
No 4 0.96 (0.76, 1.22) 26% 0.26
Yes 3 1.18 (0.95, 1.47) 0% 0.40
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polyphenols could be exerted through an indirect action 
and through triggering defence mechanisms, carcinogenic 
detoxification, and activation or suppression of onco-
suppressors and proto-oncogenes, respectively [43–45]. 
Additionally, it has been demonstrated that coffee 
intake improves metabolic features, both in women and 
men, which in turn could affect the association between 
cardio-metabolic conditions and certain cancers related 
to impaired metabolism and hormonal homeostasis 
[3, 46–49]. However, the results of the present meta-
analysis showed that it is not likely a direct association 
between coffee consumption and ovarian cancer. A 
possible reason related to lack of effects of its polyphenol 
content may depend on their bioavailability [50]; in fact, it 
is still questionable which are the polyphenol metabolites 
reaching the target tissues, what is their amount, and 
whether they can actually exert any protective effects 
specifically on the ovarian cells [51].
Another reason for lack of association retrieved 
is potential confounding effect of other foods. Coffee 
consumption might be associated with unhealthy habits 
(i.e., higher alcohol intake. smoking), which in turn could 
be related to higher risk of cancers due to a synergistic 
effect of many functional components rather than an 
individual food or beverage [52]. Moreover, it has been 
suggested that polyphenols (including those contained 
in coffee) may be effective against multiple targets in 
cancer development and progression especially whether 
in combination with other polyphenols or micronutrients, 
such as antioxidant vitamins [53, 54]. In turn, the 
potential beneficial effects of coffee might be enhanced 
or counteracted by other dietary components, resulting in 
an overall null association depending on the overall diet 
rather than coffee alone. However, this hypothesis on 
the confounding effect of other foods on coffee should 
result in null results also for the association with other 
Figure 3: Dose-response association between coffee consumption and ovarian cancer risk (A) non-linear, total analysis; (B) linear, total 
analysis (C) non-linear, postmenopausal; (D) linear, postmenopausal. 
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cancers, which in fact is not supported by other meta-
analyses showing a decreased risk of certain cancers 
associated with higher coffee consumption: thus, either the 
confounding factors are strictly related to ovarian cancer 
risk or other explanation should be further investigated.
A major strength of our meta-analysis was the 
inclusion of cohort studies carried out with a prospective 
design, which implies detailed exposure and covariate 
assessment before the diagnosis of the outcome of interest 
(that is, ovarian cancer). Moreover, we performed a dose-
response meta-analysis, which scientific value is higher 
than meta-analyses with exposure classified as high versus 
low, as it aims to investigate a possible dose-response 
relationship. However, the results of this study should be 
considered in light of some limitation. First, no stratified 
analysis was performed due to lack of available datasets, 
which prevented us from an in-depth analysis of potential 
confounders and effect modifiers, such as smoking status 
or body weight; despite our adjustment for smoking status, 
BMI index, education level and alcohol exposure, there is 
still a chance of unmeasured or residual confounding (e.g. 
menopausal status, that has not been considered in our 
analysis). Another limitation lies in the exposure assessment 
phase: the categories of low and high consumption varied 
across different studies, therefore overall estimates of high 
consumption might not be perfectly comparable; moreover, 
we don’t have data on coffee brewing methods, preparation, 
cup size, and duration of consumption. Such differences, 
if properly addressed, could yield to significant results in 
specific exposure subgroups (for instance, when analysing 
the relationship between tea consumption and ovarian 
cancer risk, a positive association has been detected for all 
tea and for black tea, but not for green tea) [55]. Similarly, 
histological information on cancer-subtype, to differentiate 
among epithelial cancer histotypes (“high grade serous” 
versus “endometrioid” versus “clear cell”), included through 
a stratified analysis, could highlight different pathological 
pathways and diversified exposure-disease relationships.
 In conclusion, the present study provided a robust 
assessment of the relationship between coffee consumption 
and ovarian cancer, which, coherently with previously 
published literature, appears null. Additional prospective 
cohort studies specifying also subgroup analyses by key 
variables (i.e., smoking status, type of coffee, etc.) are 
needed to further improve current knowledge on such topic.
Abbreviations
EPIC: European Prospective Investigation into 
Cancer and Nutrition; IWHS: Iowa Women’s Health 
Study; NBSS: National Breast Screening Study; NHS: 
The Nurses’ Health Study; NLCS: The Netherlands Cohort 
Study; NOWAC: The Norwegian Women and Cancer 
study; PLCO: Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial; SMC: The Swedish Mammography 
Cohort; VIP: Västerbotten intervention project cohort.
CONFLICTS OF INTEREST 
The authors have no conflicts of interest.
REFERENCES
1. European Coffee Federation. Coffee consumption in Europe 
[Available from: http://www.ecf-coffee.org/about-coffee/
coffee-consumption-in-europe].
2. Grosso G, Godos J, Galvano F, Giovannucci EL. Coffee, 
Caffeine, and Health Outcomes: An Umbrella Review. 
Annu Rev Nutr. 2017; 37:131–156. 
3. Marventano S, Salomone F, Godos J, Pluchinotta F, Del 
Rio D, Mistretta A, Grosso G. Coffee and tea consumption 
in relation with non-alcoholic fatty liver and metabolic 
syndrome: A systematic review and meta-analysis of 
observational studies. Clin Nutr. 2016; 35:1269–81. 
4. Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. 
Caffeinated and decaffeinated coffee consumption and risk 
of type 2 diabetes: a systematic review and a dose-response 
meta-analysis. Diabetes Care. 2014; 37:569–86. 
5. Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. 
Long-term coffee consumption and risk of cardiovascular 
disease: a systematic review and a dose-response meta-
analysis of prospective cohort studies. Circulation. 2014; 
129:643–59. 
6. Zhou Q, Luo ML, Li H, Li M, Zhou JG. Coffee consumption 
and risk of endometrial cancer: a dose-response meta-
analysis of prospective cohort studies. Sci Rep. 2015; 
5:13410. 
7. Bravi F, Tavani A, Bosetti C, Boffetta P, La Vecchia C. 
Coffee and the risk of hepatocellular carcinoma and chronic 
Table 3: Dose-response meta-analysis of prospective cohort studies on coffee consumption and ovarian cancer risk
No. of
datasets
(no. of
studies)
Coffee intake (cups/day) I
2 
(%) Pheterogeneity
Pnon-
linearity
0 1 2 3 4 5 6 7
Total analysis
Non-linear 8 (8) Ref. 1.02 (0.93, 1.12) 1.04 (0.89, 1.21) 1.05 (0.88, 1.25) 1.06 (0.88, 1.28) 1.07 (0.86, 1.34) 1.08 (0.82, 1.41) 1.09 (0.79, 1.50) –  0.55   0.85  
Linear 8 (8) Ref. 1.01 (0.97, 1.05) 1.02 (0.95, 1.10) 1.04 (0.92, 1.16) 1.05 (0.90, 1.22) 1.06 (0.88, 1.28) 1.07 (0.85, 1.35) 1.09 (0.83, 1.42) 32.91  0.17   NA 
Postmenopausal
Non-linear 3 (3) Ref. 1.06 (0.89, 1.26) 1.12 (0.84, 1.48) 1.15 (0.85, 1.56) 1.19 (0.89, 1.59) 1.22 (0.91, 1.64) 1.26 (0.91, 1.73) 1.29 (0.90, 1.86) –  0.86   0.79  
Linear 3 (3) Ref. 1.04 (0.98, 1.09) 1.08 (0.97, 1.19) 1.12 (0.95, 1.30) 1.16 (0.94, 1.42) 1.20 (0.93, 1.55) 1.24 (0.91, 1.70) 1.29 (0.90, 1.85) –  0.90   NA 
Oncotarget20814www.oncotarget.com
liver disease: a systematic review and meta-analysis of 
prospective studies. Eur J Cancer Prev. 2016.
 8. Li YM, Peng J, Li LZ. Coffee consumption associated with 
reduced risk of oral cancer: a meta-analysis. Oral Surg Oral 
Med Oral Pathol Oral Radiol. 2016; 121:381–389.e1. 
 9. Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, 
Kenfield SA. Prostate cancer progression and mortality: a 
review of diet and lifestyle factors. World J Urol. 2016.
10. Wang A, Wang S, Zhu C, Huang H, Wu L, Wan X, Yang 
X, Zhang H, Miao R, He L, Sang X, Zhao H. Coffee and 
cancer risk: A meta-analysis of prospective observational 
studies. Sci Rep. 2016; 6:33711. 
11. Godos J, Micek A, Marranzano M, Salomone F, Rio DD, 
Ray S. Coffee Consumption and Risk of Biliary Tract 
Cancers and Liver Cancer: A Dose-Response Meta-Analysis 
of Prospective Cohort Studies. Nutrients. 2017; 9:E950. 
12. Micek A, Godos J, Lafranconi A, Marranzano M, Pajak 
A. Caffeinated and decaffeinated coffee consumption 
and melanoma risk: a dose-response meta-analysis of 
prospective cohort studies. Int J Food Sci Nutr. 2017; 
11:1–10. 
13. Hashibe M, Galeone C, Buys SS, Gren L, Boffetta P, 
Zhang ZF, La Vecchia C. Coffee, tea, caffeine intake, and 
the risk of cancer in the PLCO cohort. Br J Cancer. 2015; 
113:809–16. 
14. Alicandro G, Tavani A, La Vecchia C. Coffee and cancer 
risk: a summary overview. Eur J Cancer Prev. 2017; 
26:424–32. 
15. Malerba S, Turati F, Galeone C, Pelucchi C, Verga F, La 
Vecchia C, Tavani A. A meta-analysis of prospective 
studies of coffee consumption and mortality for all causes, 
cancers and cardiovascular diseases. Eur J Epidemiol. 2013; 
28:527–39. 
16. Grosso G, Micek A, Godos J, Sciacca S, Pajak A, 
Martínez-González MA, Giovannucci EL, Galvano F. 
Coffee consumption and risk of all-cause, cardiovascular, 
and cancer mortality in smokers and non-smokers: a 
dose-response meta-analysis. Eur J Epidemiol. 2016; 
31:1191–205. 
17. Grosso G, Micek A, Godos J, Pajak A, Sciacca S, Bes-
Rastrollo M, Galvano F, Martinez-Gonzalez MA. Long-
Term Coffee Consumption Is Associated with Decreased 
Incidence of New-Onset Hypertension: A Dose-Response 
Meta-Analysis. Nutrients. 2017; 9:E890. 
18. Friberg E, Orsini N, Mantzoros CS, Wolk A. Coffee 
drinking and risk of endometrial cancer—a population-
based cohort study. Int J Cancer. 2009; 125:2413–17. 
19. WHO. http://globocan.iarc.fr/Default.aspx [Available from: 
http://globocan.iarc.fr/Default.aspx.]
20. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-
Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook 
R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, et 
al, and Global Burden of Disease Cancer Collaboration. 
The Global Burden of Cancer 2013. JAMA Oncol. 2015; 
1:505–27. 
21. Yu X, Bao Z, Zou J, Dong J. Coffee consumption and risk 
of cancers: a meta-analysis of cohort studies. BMC Cancer. 
2011; 11:96.
22. Wells GA, O’Connell D, Peterson J, Welch V, Losos M, 
Tugwell P, editors. The Newcastle-Ottawa Scale (NOS) 
for assessing the quality of nonrandomised studies in 
meta-analyses. Ottawa, Canada: Ottawa Health Research 
Institute; 1999.
23. Greenland S. Quantitative methods in the review of 
epidemiologic literature. Epidemiol Rev. 1987; 9:1–30. 
24. Greenland S, Longnecker MP. Methods for trend estimation 
from summarized dose-response data, with applications to 
meta-analysis. Am J Epidemiol. 1992; 135:1301–09. 
25. Orsini NB, Greenland S. Generalized least squares for trend 
estimation of summarized dose-response data. Stata J. 2006; 
6:40–57.
26. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-
analysis for linear and nonlinear dose-response relations: 
examples, an evaluation of approximations, and software. 
Am J Epidemiol. 2012; 175:66–73. 
27. Braem MG, Onland-Moret NC, Schouten LJ, Tjønneland 
A, Hansen L, Dahm CC, Overvad K, Lukanova A, Dossus 
L, Floegel A, Boeing H, Clavel-Chapelon F, Chabbert-
Buffet N, et al. Coffee and tea consumption and the risk 
of ovarian cancer: a prospective cohort study and updated 
meta-analysis. Am J Clin Nutr. 2012; 95:1172–81. 
28. Larsson SC, Wolk A. Coffee consumption is not associated 
with ovarian cancer incidence. Cancer Epidemiol 
Biomarkers Prev. 2005; 14:2273–74.
29. Lueth NA, Anderson KE, Harnack LJ, Fulkerson JA, 
Robien K. Coffee and caffeine intake and the risk of ovarian 
cancer: the Iowa Women’s Health Study. Cancer Causes 
Control. 2008; 19:1365–72. 
30. Lukic M, Licaj I, Lund E, Skeie G, Weiderpass E, Braaten T. 
Coffee consumption and the risk of cancer in the Norwegian 
Women and Cancer (NOWAC) Study. Eur J Epidemiol. 
2016; 31:905–16. 
31. Nilsson LM, Johansson I, Lenner P, Lindahl B, Van Guelpen 
B. Consumption of filtered and boiled coffee and the risk of 
incident cancer: a prospective cohort study. Cancer Causes 
Control. 2010; 21:1533–44. 
32. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Intake 
of coffee and tea and risk of ovarian cancer: a prospective 
cohort study. Nutr Cancer. 2007; 58:22–27. 
33. Steevens J, Schouten LJ, Verhage BA, Goldbohm RA, van 
den Brandt PA. Tea and coffee drinking and ovarian cancer 
risk: results from the Netherlands Cohort Study and a meta-
analysis. Br J Cancer. 2007; 97:1291–94. 
34. Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson 
SE. Caffeine, alcohol, smoking, and the risk of incident 
epithelial ovarian cancer. Cancer. 2008; 112:1169–77. 
Oncotarget20815www.oncotarget.com
35. Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic 
acid and chlorogenic acid, two common catechol-containing 
coffee polyphenols. Carcinogenesis. 2006; 27:269–77. 
36. Lee KJ, Jeong HG. Protective effects of kahweol and 
cafestol against hydrogen peroxide-induced oxidative stress 
and DNA damage. Toxicol Lett. 2007; 173:80–87. 
37. Kalthoff S, Landerer S, Reich J, Strassburg CP. Protective 
effects of coffee against oxidative stress induced by the 
tobacco carcinogen benzo[α]pyrene. Free Radic Biol Med. 
2017; 108:66–76. 
38. Park GH, Song HM, Jeong JB. Kahweol from Coffee 
Induces Apoptosis by Upregulating Activating Transcription 
Factor 3 in Human Colorectal Cancer Cells. Biomol Ther 
(Seoul). 2017; 25:337–43. 
39. Liang N, Kitts DD. Antioxidant property of coffee 
components: assessment of methods that define mechanisms 
of action. Molecules. 2014; 19:19180–208. 
40. Hogervorst JG, Schouten LJ, Konings EJ, Goldbohm 
RA, van den Brandt PA. A prospective study of dietary 
acrylamide intake and the risk of endometrial, ovarian, and 
breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 
16:2304–13. 
41. Grosso G, Godos J, Lamuela-Raventos R, Ray S, Micek 
A, Pajak A, Sciacca S, D’Orazio N, Del Rio D, Galvano 
F. A comprehensive meta-analysis on dietary flavonoid 
and lignan intake and cancer risk: level of evidence and 
limitations. Mol Nutr Food Res. 2017; 61:1600930. 
42. Grosso G, Micek A, Godos J, Pajak A, Sciacca S, Galvano F, 
Giovannucci EL. Dietary Flavonoid and Lignan Intake and 
Mortality in Prospective Cohort Studies: Systematic Review 
and Dose-Response Meta-Analysis. Am J Epidemiol. 2017; 
185:1304–16. 
43. Milenkovic D, Jude B, Morand C. miRNA as molecular 
target of polyphenols underlying their biological effects. 
Free Radic Biol Med. 2013; 64:40–51. 
44. Wierzejska R. Coffee consumption vs. cancer risk - a review 
of scientific data. Rocz Panstw Zakl Hig. 2015; 66:293–98.
45. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber 
WW, Schilter B. Cafestol and kahweol, two coffee specific 
diterpenes with anticarcinogenic activity. Food Chem 
Toxicol. 2002; 40:1155–63. 
46. Kim K, Kim K, Park SM. Association between the 
Prevalence of Metabolic Syndrome and the Level of Coffee 
Consumption among Korean Women. PLoS One. 2016; 
11:e0167007. 
47. Grosso G, Stepaniak U, Micek A, Topor-Mądry R, Pikhart 
H, Szafraniec K, Pająk A. Association of daily coffee and 
tea consumption and metabolic syndrome: results from 
the Polish arm of the HAPIEE study. Eur J Nutr. 2015; 
54:1129–37.
48. Micek A, Grosso G, Polak M, Kozakiewicz K, Tykarski 
A, Puch Walczak A, Drygas W, Kwasniewska M, Pajak 
A. Association between tea and coffee consumption and 
prevalence of metabolic syndrome in Poland - results from 
the WOBASZ II study (2013-2014). Int J Food Sci Nutr. 
2017; 69:358-368.
49. Takami H, Nakamoto M, Uemura H, Katsuura S, 
Yamaguchi M, Hiyoshi M, Sawachika F, Juta T, Arisawa 
K. Inverse correlation between coffee consumption and 
prevalence of metabolic syndrome: baseline survey of the 
Japan Multi-Institutional Collaborative Cohort (J-MICC) 
Study in Tokushima, Japan. J Epidemiol. 2013; 23:12–20. 
50. Martini D, Del Bo’ C, Tassotti M, Riso P, Del Rio D, 
Brighenti F, Porrini M. Coffee Consumption and Oxidative 
Stress: A Review of Human Intervention Studies. 
Molecules. 2016; 21:E979. 
51. Koehnlein EA, Koehnlein EM, Corrêa RC, Nishida VS, 
Correa VG, Bracht A, Peralta RM. Analysis of a whole 
diet in terms of phenolic content and antioxidant capacity: 
effects of a simulated gastrointestinal digestion. Int J Food 
Sci Nutr. 2016; 67:614–23. 
52. Grosso G, Bella F, Godos J, Sciacca S, Del Rio D, Ray S, 
Galvano F, Giovannucci EL. Possible role of diet in cancer: 
systematic review and multiple meta-analyses of dietary 
patterns, lifestyle factors, and cancer risk. Nutr Rev. 2017; 
75:405–19. 
53. Niedzwiecki A, Roomi MW, Kalinovsky T, Rath 
M. Anticancer Efficacy of Polyphenols and Their 
Combinations. Nutrients. 2016; 8:E552. 
54. Stedile N, Canuto R, Col CD, Sene JS, Stolfo A, Wisintainer 
GN, Henriques JA, Salvador M. Dietary total antioxidant 
capacity is associated with plasmatic antioxidant capacity, 
nutrient intake and lipid and DNA damage in healthy 
women. Int J Food Sci Nutr. 2016; 67:479–88. 
55. Leung AC, Cook LS, Swenerton K, Gilks B, Gallagher 
RP, Magliocco A, Steed H, Köbel M, Nation J, Brooks-
Wilson A, Le ND. Tea, coffee, and caffeinated beverage 
consumption and risk of epithelial ovarian cancers. Cancer 
Epidemiol. 2016; 45:119–25.
